Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patien

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patien

Item

http://www.wikidata.org/entity/Q40470332

Q40470332

about

Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance.The use and risks of antibiotics in critically ill patients.Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.An overview on severe infections in Europe.Piperacillin-tazobactam as alternative to carbapenems for ICU patients.Selection of piperacillin/tazobactam infusion mode guided by SOFA score in cancer patients with hospital-acquired pneumonia: a randomized controlled study.Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.[Bacterial sepsis : Diagnostics and calculated antibiotic therapy].Optimization and evaluation of piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics via the hollow-fiber infection model and mechanism-based modeling.Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model.Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years

P2860

Q36760879-A52BF6D4-BF4C-4C43-9ECA-CFC631908A9F Q36970989-BE09CD0C-781C-48AC-8F7A-384D9017A228 Q37642084-396C94F1-E7C6-479F-97BB-E47B9662196C Q38705266-ACFF196A-EE01-46C9-9FDA-A5D345B92308 Q38767901-43F22670-347F-47F3-9D9E-FBAF4976E85A Q39167693-28AF88D7-4196-4173-8C77-36AB086F3DA2 Q39344408-392346BD-6104-40B1-88D3-AB42729679EE Q39613942-78615869-23E0-40E9-8FEE-9DB3AB4DC95D Q40403159-D12ED92E-BD54-4228-84C1-782BF9341EA7 Q45711115-572F3BBB-E98A-4400-B591-0E3DCCE13CC6 Q47213579-773FD7D3-9431-46D7-B574-4AFE144F19C0 Q47861094-E3994492-623F-487C-B093-EAFBBADB23ED Q49589601-EABD19CA-CF9D-4EB3-A389-989874886AA1 Q49792113-4AE59974-95BE-4A60-9CEA-0657EA576367 Q50044377-0D87784F-D51C-462A-B1E8-B25A40A80034 Q54257517-BC66DD0B-2886-46AD-A4E2-D805B9C95128 Q54261873-BAC6DA09-8E2A-476D-B7E3-6941BEAA33C2 Q57815074-9E805933-02CC-491E-9CA3-6D70830E9C4B Q58701649-C0A128F1-6E96-4DCC-85CB-8D202BC67138 Q58795590-91EEDB01-FB31-45F1-AFBB-A5C50CE703C9

P2860

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patien

Item

http://www.wikidata.org/entity/Q40470332

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Is prolonged infusion of piper ...... in Intensive care unit patien

@en

type

Item

label

Is prolonged infusion of piper ...... in Intensive care unit patien

@en

prefLabel

Is prolonged infusion of piper ...... in Intensive care unit patien

@en

P1476

Is prolonged infusion of piper ...... in Intensive care unit patien

@en

P2093

Claude Martin

http://www.w3.org/2001/XMLSchema#string

DALI Study Group

http://www.w3.org/2001/XMLSchema#string

George Dimopoulos

http://www.w3.org/2001/XMLSchema#string

Jan J De Waele

http://www.w3.org/2001/XMLSchema#string

Joel Dulhunty

http://www.w3.org/2001/XMLSchema#string

Kirsi-Maija Kaukonen

http://www.w3.org/2001/XMLSchema#string

Matteo Bassetti

http://www.w3.org/2001/XMLSchema#string

Mohd H Abdul-Aziz

http://www.w3.org/2001/XMLSchema#string

Philippe Montravers

http://www.w3.org/2001/XMLSchema#string

Steven C Wallis

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections

Prediction of creatinine clearance from serum creatinine

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?

Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials.

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.

Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.

Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials.

P304

196-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKV288

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26433783

http://www.w3.org/2001/XMLSchema#string

P921

antibiotic

intensive care unit

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patien

about

P2860

P2860

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patien

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921